Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director · President, R&D · 10% owner | September 04, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,302,145 |
Ending reported balance
After 2026-09-04 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 520 · Balance 1,326,625 F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-09-04 · Sale · Disposed 2,006 · Balance 1,324,619 F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 3 · 2026-09-04 · Sale · Disposed 3,267 · Balance 1,321,352 F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 4 · 2026-09-04 · Sale · Disposed 3,962 · Balance 1,317,390 F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 5 · 2026-09-04 · Sale · Disposed 3,180 · Balance 1,314,210 F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2026-09-04 · Sale · Disposed 3,392 · Balance 1,310,818 F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2026-09-04 · Sale · Disposed 2,320 · Balance 1,308,498 F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2026-09-04 · Sale · Disposed 1,242 · Balance 1,307,256 F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 9 · 2026-09-04 · Sale · Disposed 1,992 · Balance 1,305,264 F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 10 · 2026-09-04 · Sale · Disposed 565 · Balance 1,304,699 F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 11 · 2026-09-04 · Sale · Disposed 1,329 · Balance 1,303,370 F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 12 · 2026-09-04 · Sale · Disposed 826 · Balance 1,302,544 F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 13 · 2026-09-04 · Sale · Disposed 399 · Balance 1,302,145 F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Spousal Trust | 90,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 90,000 F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Suma Mani Krishnan Trust | 51,010 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 51,010 F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 50,000 F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 399 | $366.56 | $146,255.84 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 13 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,302,145 F15 · price: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 826 | $365.41 | $301,831.88 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 12 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,302,544 F14 · price: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,329 | $364.48 | $484,390.07 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,303,370 F13 · price: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 565 | $363.34 | $205,287.33 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,304,699 F12 · price: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,992 | $362.65 | $722,404.18 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,305,264 F11 · price: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,242 | $361.61 | $449,119.62 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,307,256 F10 · price: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,320 | $360.47 | $836,281.12 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,308,498 F9 · price: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,392 | $359.39 | $1,219,037.99 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,310,818 F8 · price: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,180 | $358.42 | $1,139,776.55 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,314,210 F7 · price: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,962 | $357.57 | $1,416,708.98 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,317,390 F6 · price: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,267 | $356.37 | $1,164,253.93 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,321,352 F5 · price: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,006 | $355.57 | $713,277.23 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,324,619 F4 · price: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:15 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 520 | $354.54 | $184,360.80 |
DisclosureSEC source: 0001298711-26-000009 · wk-form4_1788563746.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,326,625 F1 · kind: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2 · price: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 240 | $311.65 | $74,796.00 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,378,155 F12 · price: The transaction was executed in multiple trades ranging from $311.50 to $311.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,039 | $310.94 | $634,000.54 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,378,395 F11 · price: The transaction was executed in multiple trades ranging from $310.44 to $311.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,801 | $309.95 | $868,156.23 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,380,434 F10 · price: The transaction was executed in multiple trades ranging from $309.43 to $310.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,803 | $308.89 | $1,174,707.91 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,383,235 F9 · price: The transaction was executed in multiple trades ranging from $308.38 to $309.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 12,729 | $307.81 | $3,918,070.21 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,387,038 F8 · price: The transaction was executed in multiple trades ranging from $307.38 to $308.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,348 | $307.09 | $413,963.79 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,399,767 F7 · price: The transaction was executed in multiple trades ranging from $306.38 to $307.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 480 | $305.87 | $146,815.20 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,401,115 F6 · price: The transaction was executed in multiple trades ranging from $305.19 to $306.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 400 | $304.89 | $121,957.56 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,401,595 F5 · price: The transaction was executed in multiple trades ranging from $304.07 to $304.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 247 | $303.17 | $74,883.06 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,401,995 F4 · price: The transaction was executed in multiple trades ranging from $303.05 to $303.77. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 593 | $302.25 | $179,234.72 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,402,242 F3 · price: The transaction was executed in multiple trades ranging from $302.05 to $303.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:40 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 320 | $300.75 | $96,240.00 |
DisclosureSEC source: 0001298711-26-000006 · wk-form4_1780699235.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,402,835 F1 · kind: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025, and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,700 | $266.42 | $452,918.08 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,403,155 F12 · price: The transaction was executed in multiple trades ranging from $266 to $266.93. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,000 | $265.16 | $1,590,979.20 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,404,855 F11 · price: The transaction was executed in multiple trades ranging from $265 to $265.73. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,852 | $264.64 | $1,284,019.21 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,410,855 F10 · price: The transaction was executed in multiple trades ranging from $264 to $264.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,248 | $263.58 | $592,534.81 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,415,707 F9 · price: The transaction was executed in multiple trades ranging from $263 to $263.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,938 | $262.35 | $508,430.23 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,417,955 F8 · price: The transaction was executed in multiple trades ranging from $262 to $262.8. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,931 | $261.41 | $766,198.28 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,419,893 F7 · price: The transaction was executed in multiple trades ranging from $261 to $261.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,667 | $260.37 | $954,762.49 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,422,824 F6 · price: The transaction was executed in multiple trades ranging from $259.98 to $260.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 668 | $259.61 | $173,419.15 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,426,491 F5 · price: The transaction was executed in multiple trades ranging from $258.98 to $259.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 589 | $258.54 | $152,280.30 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,427,159 F4 · price: The transaction was executed in multiple trades ranging from $257.93 to $258.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 23:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 407 | $257.32 | $104,728.67 |
DisclosureSEC source: 0001298711-26-000004 · wk-form4_1772839386.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,427,748 F1 · kind: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2 · shares: The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. F3 · price: The transaction was executed in multiple trades ranging from $256.68 to $257.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantPerformance Stock Units · Derivative | 43,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 17 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,536 Underlying: Common Stock · 43,536 shares Expires not disclosed F18 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the three year performance period, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on the vesting date. F19 · shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting of this PSU award. F20 · derivative.exercise_date: If any applicable portion of the performance criteria have been achieved, the PSU award shall cliff vest on February 27, 2029. F21 · derivative.expiration_date: If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 7,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 16 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,256 Underlying: Common Stock · 7,256 shares Expires not disclosed F16 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. F17 · derivative.exercise_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. F17 · derivative.expiration_date: The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 18,100 | $0.00 Strike: $275.64 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 15 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,100 Underlying: Common Stock · 18,100 shares Expires 2036-02-26 F15 · derivative.exercise_date: The stock options vest in four equal annual installments beginning on February 27, 2027. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 14 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026. F4 · derivative.exercise_date: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026. F4 · derivative.expiration_date: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · derivative · entry 13 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026. F1 · derivative.exercise_date: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026. F1 · derivative.expiration_date: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 2,605 | $275.64 | $718,042.20 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,500,253 F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F13 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 5,725 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 5,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,502,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F12 · shares: 22,900 restricted stock units ("RSUs") were granted on February 28, 2025, to the Reporting Person's spouse, Krish S. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 11,942 | $275.64 | $3,291,692.88 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,497,133 F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F11 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 26,250 PSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,509,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F10 · shares: 52,500 PSUs were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's spouse continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 3,981 | $275.64 | $1,097,322.84 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,482,825 F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F9 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 8,750 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,486,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the second installment, or 8,750 RSUs, vesting on February 27, 2026. F7 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 1,820 | $275.64 | $501,664.80 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,428,155 F5 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,000 RSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,429,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 10,236 | $275.64 | $2,821,451.04 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,425,975 F2 · shares: Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 22,500 PSUs on February 27, 2026. F3 · price: The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:33 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-26-000002 · wk-form4_1772580780.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,436,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 19 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,478,056 F21 · kind: Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.